Compare Hims and Hers Health Inc (HIMS) vs Novavax Inc (NVAX) Price & Performance

Hims & Hers Health trades at $32.70, down 0.43% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported 2025 revenue of $2.35 billion and net income of $128.37 million, though 2026 projections indicate a net loss. Recent news highlights executive departures and anticipation for Q2 2026 earnings on August 10, 2026.

The investment outlook is cautiously optimistic, supported by a 35% analyst buy rating and a $33.57 consensus price target. Key opportunities include growth in the weight-loss drug segment and international expansion. Risks involve profitability volatility, intense competition, and reliance on telehealth regulatory frameworks. The stock's valuation remains elevated with a P/E of 57.14, demanding strong future earnings growth to justify current levels.

Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.

Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.